1%) in intentional APAP overdose patients who receive NAC promptly. However, nearly 50% of the APAP ALF cases are attributed to ''therapeutic misadventures''-patients who frequently ingest multiple APAP-containing products and present with more advanced encephalopathy and liver injury. 3 Because there are at least 500 deaths each year in the United States attributed to APAP overdose, there are increasing calls for regulatory actions regarding APAP dosing, dispensing, packaging, and coformulation with opioid analgesics.
Diagnosis and Clinical Presentation
Most patients with APAP overdose have minimal or nonspecific symptoms such as malaise, abdominal pain or nausea, and vomiting at presentation. A detailed medication history can help ascertain total APAP exposure but can be challenging in patients with polydrug overdose or advanced encephalopathy. The Rumack-Matthew nomogram to predict the likelihood of hepatotoxicity is recommended for initial assessment of all patients with a single time-point overdose ( Fig. 1) . 4 Although APAP is rapidly absorbed from the gastrointestinal tract, a repeat serum APAP level 4 hours after initial presentation is advisable to better define the risk of liver injury. Of note, the serum APAP level may be low or undetectable in patients who overdose over several days, and NAC should not be delayed whenever there is any clinical suspicion of APAP overdose. Serum acetaminophenprotein adducts are covalent adducts of APAP with a much longer half-life than the parent compound, which can be a helpful diagnostic tool in ambiguous cases, but this assay is not commercially available.
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Serum aminotransferase levels are frequently normal shortly after intentional APAP overdose but may rapidly increase during the first 24 hours of hospitalization. Some subjects may present with an isolated metabolic or lactic acidosis with or without acute kidney injury or an elevation in their international normalized ratio (INR) ( Table 2 ). All patients with elevated serum aminotransferase levels should be evaluated for other etiologies of acute liver injury (ie hepatitis A, B, C; ischemia; pancreaticobiliary disease), as well as ingestion of other illicit substances (Table 2) . A rapid assessment of the severity of liver injury is performed by a combination of clinical (grade of encephalopathy) and laboratory (liver chemistries, creatinine, INR, arterial PH, arterial lactate, and factor V assay) parameters. An early assessment of disease severity can help determine the 
Standard Treatment
All patients who present within 4 hours of APAP overdose should receive ipecac syrup to induce vomiting-or nasogastric lavage to remove pill fragments, followed by activated charcoal to reduce APAP absorption. NAC, which repletes the intrahepatic glutathione stores, also should be administered promptly via oral or intravenous (IV) route based on the patient' s clinical condition. 4 Of note, NAC is a pungent sulfa drug that can cause significant nausea and vomiting in 20% to 30% of patients, and IV NAC can lead to rash and a non-IgE-mediated hypersensitivity reaction. Recently, a randomized trial has shown better tolerance and fewer side effects with a 12-hour IV regimen of NAC versus the standard 20-hour IV regimen, but confirmatory studies are needed 6 ( Table 3 ). The incidence of hepatotoxicity is < 10% in those receiving NAC within 8 hours of ingestion but increases to 40% if NAC is delayed > 16 hours. The goal of supportive care is to provide the optimal environment for hepatic recovery, vital organ support, and prevention and treatment of complications. General supportive measures include volume resuscitation and vasopressor support, monitoring for bleeding complications, monitoring and treatment of infections, respiratory support, avoidance of nephrotoxins, and renal support as needed. 7 Monitoring and treatment of hypoglycemia and hypophosphatemia are also important. Therefore, liver chemistries, renal function, INR, acid base status, and factor V should be checked every 12 hours. Subjects with no evidence of liver injury, coagulopathy, or kidney injury at 24 hours after presentation may have NAC discontinued and be treated supportively. In contrast, patients with evidence of early liver injury should receive a full 72 hours of NAC therapy, and those with poor prognostic indicators should be identified for early liver transplantation (LT) evaluation (Table 4) .
Prognosis and Outcomes
Transplant-free survival from APAP-related ALF is significantly higher (70%) compared to ALF from idiosyncratic drug reactions (< 25%) or other causes of ALF (0%-50%). 8 Multiple prognostic scoring systems have been evaluated to identify the patients at increased risk of death without LT from APAP ALF (Table 3) . 9 The King' s College criteria with or without arterial lactate levels are the most commonly used criteria to list patients for LT. In a large multicenter prospective study of 275 APAP ALF patients, 178 (65%) patients survived without LT, 23 (8%) patients underwent LT, and 74 (27%) patients died. 3 The Apache II (Acute Physiology and Chronic Health Evaluation II) score yielded higher sensitivity but slightly lower specificity than King' s College criteria. One-year survival after LT for APAP ALF is 73%. 10 For APAP hepatotoxicity patients not requiring LT, the mean length of stay for intentional overdose patients is 4 days, and for nonintentional overdose patients it is 9 days.
Prevention of Acetaminophen Overdose
Several steps have been taken by regulatory authorities to change the labeling and dispensing of the hundreds of prescription and over-the-counter (OTC) products containing APAP (Table 5 ). In 1998, the United Kingdom limited the sale of OTC APAP to 8 grams and required blister packaging of APAP products. This resulted in significant decrease in the APAP overdose cases, number of admissions to liver units, and number of liver transplants due to APAP overdose. 11 In 2006, the FDA enacted changes in the labeling of Oral loading: 140 mg/kg followed by 70 mg/kg every 4 hours for 17 doses or until INR < 1.5 nausea and vomiting in 20%, mix with carbonated beverages to improve tolerance; prochlorperazine (Compazine) 10 mg, metoclopramide (Reglan) 10 mg, or ondansetron (Zofran) 4 mg by mouth or IV; consider IV NAC if refractory nausea and vomiting Intravenous loading: 150 mg/kg in 250 ml dextrose 5% over 1 hour, then 50 mg/kg in 500 ml dextrose 5% over 4 hours; then 125 mg/kg in 1000 ml dextrose 5% over 19 hours; 100 mg/kg in 1000 ml dextrose 5% over 24 hours for 2 days or until INR is less than 1. all OTC products that contain APAP to include extra warnings. More recently, the FDA has limited the dose of APAP in prescription combination products to a maximum of 325 mg per tablet and also included black-box warnings on these products regarding their APAP content. In addition to regulatory actions, patient education by health care providers is extremely important. The American Gastroenterological Association (AGA) has launched an innovative campaign comprising of a short online video (http: //gutcheck.gastro.org) and other education materials to help raise awareness among patients regarding OTC and prescription medications containing APAP. However, a recent prospective study has demonstrated the limitations of written and even verbal instructions to patients regarding the potential for inadvertent APAP toxicity when using multiple products.
